Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)

CAPS Rating: 4 out of 5

A biotechnology company specializing in the detailed structural analysis of complex mixture drugs of the development of generic or biosimilar versions of complex drug products as well as to the discovery and development of novel drugs.

Recs

0
Player Avatar LifeScientist (35.03) Submitted: 11/27/2012 8:37:20 PM : Outperform Start Price: $10.24 MNTA Score: +3.92

definitely a momentum and technical play; there appear to be no financials or pipeline worth mentioning in the very short run, but I thumbs up on the technicals and a 2013 pipeline possible events or licensing

Featured Broker Partners


Advertisement